Kenneth J. Hillan's Insider Trades & SAST Disclosures
Kenneth J. Hillan's most recent trade in Sangamo Therapeutics Inc was a trade of 50,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 4, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Kenneth J. Hillan.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Sangamo Therapeutics Inc | Kenneth J. Hillan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2024 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) | |
| Sangamo Therapeutics Inc | Kenneth J. Hillan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2024 | 25,000 | 74,600 (0%) | 0% | 0 | Common Stock | |
| Zymeworks BC Inc | Hillan J. Kenneth | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Dec 2023 | 37,000 | 37,000 | - | - | Stock Option (Right to Buy) | |
| 23andMe Holding Co - Ordin... | Kenneth J. Hillan | Chief Therapeutics Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2023 | 44,381 | 237,223 | - | 0 | Class A Common Stock | |
| 23andMe Holding Co - Ordin... | Kenneth J. Hillan | Chief Therapeutics Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.08 per share. | 05 Jun 2023 | 15,347 | 221,876 | - | 2.1 | 31,922 | Class A Common Stock |
| Sangamo Therapeutics Inc | Kenneth J. Hillan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 27,750 | 27,750 | - | - | Stock Option (Right to Buy) | |
| Sangamo Therapeutics Inc | Kenneth J. Hillan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 13,900 | 49,600 (0%) | 0% | 0 | Common Stock | |
| 23andMe Holding Co - Ordin... | Kenneth J. Hillan | Chief Therapeutics Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.94 per share. | 20 May 2023 | 4,628 | 192,842 | - | 1.9 | 8,978 | Class A Common Stock |
| 23andMe Holding Co - Ordin... | Kenneth J. Hillan | Chief Therapeutics Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.87 per share. | 20 Feb 2023 | 5,457 | 191,705 | - | 2.9 | 15,662 | Class A Common Stock |
| Zymeworks BC Inc | Kenneth J. Hillan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Dec 2022 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| 23andMe Holding Co - Ordin... | Kenneth J. Hillan | Chief Therapeutics Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.99 per share. | 20 Nov 2022 | 4,628 | 197,162 | - | 3.0 | 13,838 | Class A Common Stock |
| 23andMe Holding Co - Ordin... | Kenneth J. Hillan | Chief Therapeutics Officer | Sale of securities on an exchange or to another person at price $ 3.64 per share. | 24 Aug 2022 | 8,753 | 196,083 | - | 3.6 | 31,861 | Class A Common Stock |
| 23andMe Holding Co - Ordin... | Kenneth J. Hillan | Chief Therapeutics Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.33 per share. | 20 Aug 2022 | 4,628 | 204,836 | - | 3.3 | 15,411 | Class A Common Stock |
| 23andMe Holding Co - Ordin... | Kenneth J. Hillan | Chief Therapeutics Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.82 per share. | 01 Jun 2022 | 4,627 | 209,464 | - | 2.8 | 13,048 | Class A Common Stock |
| Sangamo Therapeutics Inc | Kenneth J. Hillan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2022 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Sangamo Therapeutics Inc | Kenneth J. Hillan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2022 | 12,500 | 35,700 (0%) | 0% | 0 | Common Stock | |
| Sangamo Therapeutics Inc | Kenneth J. Hillan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 16,400 | 16,400 | - | - | Stock Option (Right to Buy) | |
| Sangamo Therapeutics Inc | Kenneth J. Hillan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 8,200 | 23,200 (0%) | 0% | 0 | Common Stock | |
| Sangamo Therapeutics Inc | Kenneth J. Hillan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Sep 2020 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Sangamo Therapeutics Inc | Kenneth J. Hillan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Sep 2020 | 15,000 | 15,000 (0%) | 0% | 0 | Common Stock | |
| Zymeworks BC Inc | Kenneth J. Hillan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 May 2020 | 9,000 | 9,000 | - | - | Stock Option (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges